CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)
Engineered immune cells delivered directly into the brain or spinal fluid. Some children with an incurable brainstem tumour have had striking, if temporary, responses.
City of Hope IL13Rα2 CAR-T (intraventricular; one complete response 2016, phase 1 of 65 patients 2024 with 50% stable disease or better). Stanford GD2 CAR-T for H3K27M diffuse midline glioma (Majzner/Monje; Nature 2022 and 2024: radiographic and clinical improvement in most, one durable complete response). Penn EGFRvIII CAR-T showed antigen loss; dual-target CARv3-TEAM-E (MGH, 2024-26) and multi-antigen and locoregional approaches follow. Barriers: heterogeneity, antigen loss, exhaustion, neurotoxicity in a closed space.
How it works
Locoregional (intraventricular or intratumoural) delivery of CAR-T against glioma-restricted antigens, often repeated.
- Bypasses BBB via direct CNS delivery
- Proof of activity in DIPG and recurrent GBM
- Transient responses, antigen escape
- Tumour inflammation-associated neurotoxicity (TIAN)
- Manufacturing and repeat dosing logistics
Latest papers
topQuery for this technology: (TITLE:"CAR-T for glioma" OR ABSTRACT:"CAR-T for glioma" OR TITLE:"IL13Rα2, GD2, EGFRvIII, multi-target" OR ABSTRACT:"IL13Rα2, GD2, EGFRvIII, multi-target") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), not a curated reading list.